Altogether, our data strongly support that DRB1*15:01-dependent and DNA methylation-mediated levels of expression, together with the structural characteristics of the DRB1*15:01 molecule, contribute to MS risk. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.